EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month target prices for EyePoint Pharmaceuticals' shares. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they expect the company's stock price to reach $32.67 in the next year. This suggests a possible upside of 1,183.6% from the stock's current price.
View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts.

EyePoint Pharmaceuticals' stock was trading at $3.50 on January 1st, 2023. Since then, EYPT shares have decreased by 27.3% and is now trading at $2.5450.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EYPT earnings forecast.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its earnings results on Wednesday, November, 3rd. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.11. The company earned $9.06 million during the quarter, compared to analysts' expectations of $9.60 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 58.08% and a negative net margin of 246.97%. During the same quarter in the prior year, the company earned ($0.30) EPS.

Shares of EyePoint Pharmaceuticals reverse split on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

EyePoint Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Franklin Resources Inc. (16.94%), Millennium Management LLC (1.98%), Verition Fund Management LLC (1.63%), Caligan Partners LP (1.28%), Bank of America Corp DE (0.99%) and Essex Investment Management Co. LLC (0.59%).
View institutional ownership trends.

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYPT stock can currently be purchased for approximately $2.55.

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $87.29 million and generates $41.40 million in revenue each year. The company earns $-102,250,000.00 in net income (profit) each year or ($2.73) on an earnings per share basis.

The company employs 122 workers across the globe.

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.